{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:28:35Z","timestamp":1793381315958,"version":"4.5.0"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Psoriasis is a chronic multisystem inflammatory disease that affects ~0.1\u20131.5% of the world population. The classic cutaneous manifestation of psoriasis is scaly erythematous plaques, limited or widely distributed. Moreover, psoriasis could be associated with comorbidities like psoriatic arthritis, metabolic syndrome, diabetes, cardiovascular disease, nephropathy, bowel disease, and brain diseases. In this review, we suggest that psoriasis should be classified as cutaneous psoriasis or systemic psoriasis and propose the classification for distinction. This would help to better understand and manage psoriasis.<\/jats:p>","DOI":"10.3389\/fmed.2021.649408","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T18:05:01Z","timestamp":1634148301000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":74,"title":["Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction"],"prefix":"10.3389","volume":"8","author":[{"given":"Bing-Xi","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ran","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yong","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Mechanisms of disease: psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"New Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature."},{"key":"B4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/gene.2009.11","article-title":"Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis","volume":"10","author":"Elder","year":"2009","journal-title":"Genes Immun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/jid.2009.319","article-title":"Molecular dissection of psoriasis: integrating genetics and biology","volume":"130","author":"Elder","year":"2010","journal-title":"J Investigat Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.3390\/ijms20184347","article-title":"Risk factors for the development of psoriasis","volume":"20","author":"Kamiya","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA."},{"key":"B9","doi-asserted-by":"publisher","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/jid.2011.365","article-title":"Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom","volume":"132","author":"Langan","year":"2012","journal-title":"J Invest Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jaad.2005.11.1079","article-title":"Psoriasis is associated with lipid abnormalities at the onset of skin disease","volume":"54","author":"Mallbris","year":"2006","journal-title":"J Am Acad Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/JID.2015.385","article-title":"Characterization of lipoprotein composition and function in pediatric psoriasis reveals a more atherogenic profile","volume":"136","author":"Tom","year":"2016","journal-title":"J Invest Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","article-title":"Psoriasis: Which therapy for which patient: psoriasis comorbidities and preferred systemic agents","volume":"80","author":"Kaushik","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis\u2013oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica."},{"key":"B17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s13555-021-00523-x","article-title":"Nail psoriasis: a review of effective therapies and recommendations for management","volume":"11","author":"Hadeler","year":"2021","journal-title":"Dermatol Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.3899\/jrheum.201471","article-title":"Nail psoriasis: diagnosis, assessment, treatment options, and unmet clinical needs","volume":"48","author":"Kaeley","year":"2021","journal-title":"J Rheumatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1468-3083.2009.03364.x","article-title":"Approach to managing patients with nail psoriasis","volume":"23","author":"Reich","year":"2009","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B20","first-page":"278","article-title":"Diagnosis and management of psoriasis","volume":"63","author":"Kim","year":"2017","journal-title":"Can Fam Physician."},{"key":"B21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/01.ASW.0000550592.08674.43","article-title":"Diagnosis and management of cutaneous psoriasis: a review","volume":"32","author":"Brandon","year":"2019","journal-title":"Adv Skin Wound Care."},{"key":"B22","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/archderm.1996.03890300147032","article-title":"How great is the risk of further psoriasis following a single episode of acute guttate psoriasis?","volume":"132","author":"Martin","year":"1996","journal-title":"Arch Dermatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2147\/PTT.S98954","article-title":"Pustular psoriasis: pathophysiology and current treatment perspectives","volume":"6","author":"Benjegerdes","year":"2016","journal-title":"Psoriasis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e043666","DOI":"10.1136\/bmjopen-2020-043666","article-title":"Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare","volume":"11","author":"Choon","year":"2021","journal-title":"BMJ Open."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1111\/jdv.14949","article-title":"Generalized pustular psoriasis: a review and update on treatment","volume":"32","author":"Hoegler","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jaad.2011.01.032","article-title":"Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation","volume":"67","author":"Robinson","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/ijd.12070","article-title":"Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia","volume":"53","author":"Choon","year":"2014","journal-title":"Int J Dermatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2147\/CCID.S240607","article-title":"Diagnosis, screening and treatment of Patients with Palmoplantar Pustulosis (PPP): a review of current practices and recommendations","volume":"13","author":"Freitas","year":"2020","journal-title":"Clin Cosmet Investig Dermatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/jdv.14386","article-title":"European consensus statement on phenotypes of pustular psoriasis","volume":"31","author":"Navarini","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/PTT.S180608","article-title":"Acrodermatitis continua of Hallopeau: clinical perspectives","volume":"9","author":"Smith","year":"2019","journal-title":"Psoriasis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2147\/PTT.S101232","article-title":"Erythrodermic psoriasis: pathophysiology and current treatment perspectives","volume":"6","author":"Singh","year":"2016","journal-title":"Psoriasis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0733-8635(18)30040-8","article-title":"Pustular and erythrodermic psoriasis","volume":"13","author":"Prystowsky","year":"1995","journal-title":"Dermatol Clin."},{"key":"B33","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2147\/CCID.S189000","article-title":"Inverse psoriasis: from diagnosis to current treatment options","volume":"12","author":"Micali","year":"2019","journal-title":"Clin Cosmet Investig Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"C170","DOI":"10.12968\/hmed.2015.76.11.C170","article-title":"The Koebner phenomenon","volume":"76","author":"Ahad","year":"2015","journal-title":"Br J Hosp Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","article-title":"Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council","volume":"82","author":"Strober","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"ii65","DOI":"10.1136\/ard.2004.031237","article-title":"Psoriasis assessment tools in clinical trials","volume":"64","author":"Feldman","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaad.2019.08.049","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","article-title":"Psoriasis severity and the prevalence of major medical comorbidity: a population-based study","volume":"149","author":"Yeung","year":"2013","journal-title":"JAMA Dermatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00296-013-2876-z","article-title":"High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a cross-sectional study","volume":"34","author":"Henes","year":"2014","journal-title":"Rheumatol Int."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases Epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/1346-8138.15954","article-title":"Psoriatic arthritis","volume":"48","author":"Umezawa","year":"2021","journal-title":"J Dermatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jaad.2013.02.009","article-title":"Fingernail psoriasis reconsidered: a case-control study","volume":"69","author":"van der Velden","year":"2013","journal-title":"J Am Acad Dermatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"516","DOI":"10.2340\/00015555-3098","article-title":"Nail psoriasis: an updated review and expert opinion on available treatments, including biologics","volume":"99","author":"Bardazzi","year":"2019","journal-title":"Acta Derm Venereol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clindermatol.2017.09.005","article-title":"Psoriasis and the metabolic syndrome","volume":"36","author":"Gisondi","year":"2018","journal-title":"Clin Dermatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2340\/00015555-2657","article-title":"Risk of myocardial infarction in patients with psoriasis and psoriatic arthritis: a nationwide cohort study","volume":"97","author":"Egeberg","year":"2017","journal-title":"Acta Derm Venereol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA."},{"key":"B50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jaad.2020.03.043","article-title":"The risk of myocardial infarction, stroke, and revascularization among patients with psoriasis treated with apremilast compared with biologics and disease-modifying antirheumatic drugs: A cohort study in the US MarketScan database","volume":"83","author":"Persson","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jjcc.2018.10.008","article-title":"Risk of myocardial infarction in patients with psoriasis: a cross-sectional patient-population study in a Japanese hospital","volume":"73","author":"Shiba","year":"2019","journal-title":"J Cardiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1111\/bjd.14961","article-title":"The risk of IgA nephropathy and glomerular disease in patients with psoriasis: a population-based cohort study","volume":"176","author":"Grewal","year":"2017","journal-title":"Brit J Dermatol."},{"key":"B53","first-page":"41","article-title":"Nephropathy in patients with psoriasis","volume":"30","author":"Kreimer","year":"2016","journal-title":"J Eur Acad Dermatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"f5961","DOI":"10.1136\/bmj.f5961","article-title":"Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study","volume":"347","author":"Wan","year":"2013","journal-title":"Bmj-Brit Med J."},{"key":"B55","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jdermsci.2015.03.012","article-title":"Risk of incident chronic kidney disease and end-stage renal disease in patients with psoriasis: a nationwide population-based cohort study","volume":"78","author":"Chi","year":"2015","journal-title":"J Dermatol Sci."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1136\/annrheumdis-2012-202143","article-title":"Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women","volume":"72","author":"Li","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.jid.2020.03.473","article-title":"Real-world risk of new onset inflammatory bowel disease among psoriasis patients exposed to interleukin 17 inhibitors","volume":"140","author":"Wright","year":"2020","journal-title":"J Investigat Dermatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/ecco-jcc\/jjz152","article-title":"Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease-a systematic review and meta-analysis","volume":"14","author":"Alinaghi","year":"2020","journal-title":"J Crohns Colitis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials","volume":"78","author":"Schreiber","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/jid.2013.508","article-title":"The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis","volume":"134","author":"Dowlatshahi","year":"2014","journal-title":"J Invest Dermatol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jaad.2017.05.019","article-title":"Psoriasis and suicidality: a systematic review and meta-analysis","volume":"77","author":"Singh","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s40257-017-0281-1","article-title":"Risk of suicidality in people with psoriasis: a systematic review and meta-analysis of cohort studies","volume":"18","author":"Chi","year":"2017","journal-title":"Am J Clin Dermatol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3109\/09546634.2015.1107180","article-title":"Association between psoriasis and chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"27","author":"Ungprasert","year":"2016","journal-title":"J Dermatol Treat."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e0145221","DOI":"10.1371\/journal.pone.0145221","article-title":"Association between psoriasis and chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One."},{"key":"B65","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1468-3083.2011.04009.x","article-title":"Association between psoriasis and chronic obstructive pulmonary disease: a population-based study in Taiwan","volume":"26","author":"Chiang","year":"2012","journal-title":"J Eur Acad Dermatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jhep.2009.04.020","article-title":"Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis","volume":"51","author":"Gisondi","year":"2009","journal-title":"J Hepatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/jdv.13456","article-title":"Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis","volume":"30","author":"Gisondi","year":"2016","journal-title":"J Eur Acad Dermatol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"9308341","DOI":"10.1155\/2020\/9308341","article-title":"Psoriasis and risk of uveitis: a systematic review and meta-analysis","volume":"2020","author":"Chaiyabutr","year":"2020","journal-title":"Biomed Res Int."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/S0140-6736(18)30949-8","article-title":"Clinical management of psoriatic arthritis","volume":"391","author":"Van den Bosch","year":"2018","journal-title":"Lancet."},{"key":"B70","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","article-title":"Psoriasis prevalence among adults in the United States","volume":"70","author":"Rachakonda","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjd.19039","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update","volume":"183","author":"Smith","year":"2020","journal-title":"Br J Dermatol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1111\/jdv.16683","article-title":"Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2)","volume":"34","author":"Lambert","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1111\/jdv.16684","article-title":"Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 1)","volume":"34","author":"Lambert","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/j.jid.2021.02.743","article-title":"New frontiers in psoriatic disease research, part ii: comorbidities and targeted therapies","volume":"141","author":"Yan","year":"2021","journal-title":"J Invest Dermatol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.amjms.2021.03.009","article-title":"Treatment of psoriasis in end-stage renal disease patients is associated with decreased mortality: a retrospective cohort study","volume":"362","author":"Schwade","year":"2021","journal-title":"Am J Med Sci."},{"key":"B78","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1007\/s12325-021-01795-7","article-title":"Real-world claims analyses of comorbidity burden, treatment pattern, healthcare resource utilization, and costs in pediatric psoriasis","volume":"38","author":"Edson-Heredia","year":"2021","journal-title":"Adv Ther."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.649408\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T18:05:06Z","timestamp":1634148306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.649408\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,13]]},"references-count":78,"alternative-id":["10.3389\/fmed.2021.649408"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.649408","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,13]]},"article-number":"649408"}}